BioCentury
ARTICLE | Finance

Ebb & Flow

February 18, 2008 8:00 AM UTC

Creating a series of next generation Genentechs is not exactly a modest goal, but that is what The Column Group is setting out to do. In mid-April, the firm expects to close its first fund of about $300 million, which will be dedicated to funding "big idea" therapeutics companies.

Column Group already has made three investments out of this fund, one of which was disclosed last week. NGM, a metabolic and cardiovascular company, garnered a tranched A round of $25.5 million, which is expected to fund the company for several years. The first tranche is for $8.5 million. ...